Search hospitals > Ontario > LONDON
Children's Hospital
Claim this profileLONDON, Ontario N6A 5W9
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Global Leader in Acute Lymphoblastic Leukemia
Conducts research for Lymphoid Leukemia
Conducts research for Uterine Tumors
Conducts research for Cancer
158 reported clinical trials
19 medical researchers
Summary
Children's Hospital is a medical facility located in LONDON, Ontario. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Acute Lymphoblastic Leukemia, Lymphoid Leukemia, Uterine Tumors, Cancer and other specialties. Children's Hospital is involved with conducting 158 clinical trials across 378 conditions. There are 19 research doctors associated with this hospital, such as Shayna M. Zelcer, Terry Ponich, MD, FRCPC, Matthew Weir, MD, and Adam Power, MD.Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
Global LeaderStage II
Stage IV
Stage III
2Acute Lymphoblastic Leukemia
Global LeaderStage II
Stage IV
Stage III
Top PIs
Shayna M. ZelcerChildren's Hospital5 years of reported clinical research
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
25 reported clinical trials
70 drugs studied
Terry Ponich, MD, FRCPCVictoria Hospital1 year of reported clinical research
Studies Ulcerative Colitis
Studies Colitis
11 reported clinical trials
9 drugs studied
Matthew Weir, MDVictoria Hospital5 years of reported clinical research
Studies Contrast-induced Nephropathy
Studies Kidney Disease
4 reported clinical trials
6 drugs studied
Adam Power, MDLondon Health Sciences Centre4 years of reported clinical research
Studies Peripheral Vascular Disease
Studies Peripheral Artery Disease
3 reported clinical trials
5 drugs studied
Clinical Trials running at Children's Hospital
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Testicular cancer
Brain Tumor
Acute Leukemia
Crohn's Disease
Ovarian Tumors
Ovarian Choriocarcinoma
Ovarian Carcinoma
Leukemia
CPX-351 + Gilteritinib
for Acute Myeloid Leukemia
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone.
Recruiting2 awards Phase 3
Diagnostic Testing
for Pediatric Leukemia
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Recruiting1 award Phase 1 & 211 criteria
Revumenib + Chemotherapy
for Relapsed/Refractory Leukemia
This phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not respond to treatment (refractory) and is associated with a KMT2A (MLL) gene rearrangement (KMT2A-R). Leukemia is a cancer of the white blood cells, where too many underdeveloped (abnormal) white blood cells, called "blasts", are found in the bone marrow, which is the soft, spongy center of the bones that produces the three major blood cells: white blood cells to fight infection; red blood cells that carry oxygen; and platelets that help blood clot and stop bleeding. The blasts crowd out the normal blood cells in the bone marrow and spread to the blood. They can also spread to the brain, spinal cord, and/or other organs of the body. The leukemia cells of some children have a genetic change in which a gene (KMT2A) is broken and combined with other genes that typically do not interact with one another; this is called "rearranged". This genetic rearrangement alters how other genes are turned on or off in the cell, turning on genes that drive the development of leukemia. Patients with KMT2A rearrangement have higher risk for cancer coming back after treatment. Revumenib is an oral medicine that directly targets the changes that occur in a cell with a KMT2A rearrangement and has been shown to specifically kill these leukemia cells in preclinical laboratory settings and in animals. Drugs used in chemotherapy, such as vincristine, prednisone, asparaginase, fludarabine and cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to find out if the combination of revumenib and chemotherapy would be safe and/or effective in treating infants and young children with relapsed or refractory KMT2A-R leukemia.
Recruiting1 award Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Children's Hospital?
Children's Hospital is a medical facility located in LONDON, Ontario. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Acute Lymphoblastic Leukemia, Lymphoid Leukemia, Uterine Tumors, Cancer and other specialties. Children's Hospital is involved with conducting 158 clinical trials across 378 conditions. There are 19 research doctors associated with this hospital, such as Shayna M. Zelcer, Terry Ponich, MD, FRCPC, Matthew Weir, MD, and Adam Power, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.